Almost All Turmeric (Curcumin) Brands are a Scam

The speaker walks through common label tricks: a front label might say 'Turmeric Curcumin 1,650 mg' but the ingredients reveal most is turmeric root powder (max 10% curcumin, so only ~150 mg active). You want '95% standardized extract' to ensure high curcumin content. Even then, natural absorption is poor (<1%), so a bioavailability enhancer must be present. He cautions that piperine is widely used but likely ineffective; Novasol, which solubilizes curcumin in water, consistently raises blood levels best according to multiple analyses. Third-party testing sites like Labdoor and ConsumerLab help verify that what's on the label matches what's in the bottle—critical in a poorly regulated industry. Also, consuming with fatty foods may improve absorption. Turmeric powder (not extract) carries lead contamination risk, and some manufacturers use synthetic curcumin from fossil fuels (found in 4/23 brands tested). The speaker emphasizes he has no affiliation with any curcumin supplement.

The speaker notes that doses showing tentative benefits cluster around 500–2,000 mg of curcumin (from standardized extracts). Because curcumin’s poor bioavailability may be partially overcome by fat, he suggests taking it with fatty foods. He stresses that we lack optimal dosing guidelines for any particular condition and that the evidence is still tentative. For prediabetes, the landmark trial likely used around 1,500 mg/day; for ulcerative colitis, 2,000 mg was common. However, he does not recommend patients start curcumin without a doctor’s blessing due to potential liver injury reports. Overall, he tends to discourage patients from curcumin, but if they insist, this dosing bracket and timing advice provides a best-guess strategy.

After reviewing the ITP mouse failure, the 2017 PAINS paper, failures in Alzheimer’s and Crohn’s trials, and the ubiquitous supplement scams, Dr. Stanfield’s default advice is avoidance. He cites lead contamination, synthetic curcumin, labeling fraud, and liver injury reports as additional reasons. The only reason he even discusses a selection protocol is for patients who still want to try it despite his dissuasion. This stance is a strong departure from common wellness advice that broadly recommends turmeric/curcumin for inflammation.

The 2017 paper highlighted that curcumin's chemical structure makes it prone to non-specific interference in high-throughput assays, producing false positives. This class of compounds, known as PAINS, misleads researchers into thinking a compound is hitting a disease target when it's just chemically confusing the test. The authors noted that despite millions of dollars and thousands of papers, no FDA-approved curcumin drug had emerged—a red flag. Ten years later, this still holds; human trials in Alzheimer’s, Crohn’s, and weight loss have consistently failed or shown harm. The takeaway: enthusiasm from lab assays alone is dangerously misplaced for curcumin.

The speaker points to continued disappointments in human clinical trials: Alzheimer’s patients performed worse on cognitive tests with curcumin, Crohn’s disease recurrence was higher with curcumin than placebo, and weight loss trials showed no clinically meaningful BMI reduction without lifestyle changes. Even the rigorous ITP mouse lifespan study—which ensured absorption—showed no protective effect. This consistent failure across multiple rigorous endpoints reinforces the 2017 verdict that curcumin lacks conclusive efficacy evidence. The speaker uses this to frame the supplement market as largely a scam, with only narrow exceptions.

The speaker cites two lines of evidence: some researchers argue the form of curcumin that gets absorbed with piperine may not be the biologically active one necessary for benefit; and newer analyses—including one that also tested other enhancers—found piperine did not actually increase absorbed curcumin levels. The claim appears rooted in a single 1990s study that has not been replicated under modern scrutiny. This casts doubt on the entire category of piperine-boosted supplements and reinforces the need to question label bioavailability claims.

The speaker presents four clinical examples: In ulcerative colitis, over 50% of patients achieved remission in 4 weeks on curcumin plus standard meds vs 0% on placebo. For knee arthritis, meta-analyses showed pain and function improvements comparable to NSAIDs like diclofenac. In chronic indigestion, curcumin worked as well as omeprazole. Most striking, a 9-month prediabetes trial found 0% progression to type 2 diabetes in the curcumin group vs 16.4% with placebo, plus improved biomarkers. These results are the only areas where Dr. Stanfield would consider curcumin an option—but only with careful attention to dose, form, and brand.